CERO Overview

CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Wall Street analysts forecast CERO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CERo Therapeutics Holdings Inc revenue for the last quarter amounts to -4.72M USD, decreased -8.24

CERo Therapeutics Holdings Inc. EPS for the last quarter amounts to USD, decreased

CERo Therapeutics Holdings Inc (CERO) has 8 emplpoyees as of March 31 2026.

Today CERO has the market capitalization of 0.00 USD.